甘露醇在幕上高血压性脑出血早期治疗中的效果:系统评价与Meta分析
该系统评价与Meta分析纳入34项研究共3627例幕上高血压性脑出血患者,比较甘露醇与非甘露醇组在血肿扩大发生率、神经功能改善率、死亡率和脑水肿加重发生率上的差异。结果显示甘露醇组在所有结局指标上与非甘露醇组均有显著统计学差异(P值分别为<0.00001、<0.00001、<0.00001、P=0.0002)。作者结论认为,对于无明显颅内压增高或脑瘫症状的患者,不推荐在幕上高血压性脑出血早期常规使用甘露醇。
要点
- 纳入34项研究共3627例幕上高血压性脑出血患者,甘露醇组与非甘露醇组在所有结局指标上均有显著统计学差异。
- 亚组分析显示研究类型和干预时间对结局指标无显著影响。
- 作者结论认为,对于无明显颅内压增高或脑瘫症状的患者,不推荐在幕上高血压性脑出血早期常规使用甘露醇。
核心结论
- 对于无明显颅内压增高或脑瘫症状的患者,不推荐在幕上高血压性脑出血早期常规使用甘露醇。
- 需要更多高质量试验来证实该结论并确定甘露醇的最佳使用时间和剂量。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、EMBASE、Cochrane Library、VIP、CNKI和万方数据库。
- 纳入34项研究共3627例幕上高血压性脑出血患者,研究发表于2000年至2018年。
- 结局指标包括血肿扩大发生率、神经功能改善率、死亡率和脑水肿加重发生率。
- 亚组分析探讨研究类型、发表年份、干预时间和剂量对结局指标的影响,发表偏倚采用漏斗图评估。
主要发现
- 甘露醇组与非甘露醇组在血肿扩大发生率上差异有显著统计学意义(P < 0.00001)。
- 甘露醇组与非甘露醇组在神经功能改善率上差异有显著统计学意义(P < 0.00001)。
- 甘露醇组与非甘露醇组在死亡率上差异有显著统计学意义(P < 0.00001)。
- 甘露醇组与非甘露醇组在脑水肿加重发生率上差异有显著统计学意义(P = 0.0002)。
- 亚组分析显示研究类型和干预时间对结局指标无显著影响;发表时间(2010年后)亚组(P = 0.08)和半剂量甘露醇亚组(P = 0.20)在死亡率上无显著统计学差异。
临床怎么用
- 对于无明显颅内压增高或脑瘫症状的幕上高血压性脑出血患者,作者不推荐在早期常规使用甘露醇。
局限性
- 需要更多高质量试验来证实该结论并确定甘露醇的最佳使用时间和剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mannitol has been widely applied as a priority drug in the clinical treatment for brain edema and increased intracranial pressure after intracerebral hemorrhage. However, no consensus on the efficacy and safety of mannitol has been achieved. Our meta-analysis was conducted to assess the effect of mannitol in the early stage of supratentorial hypertensive intracerebral hemorrhage (HICH) and provided a treatment reference for clinicians. METHODS: All relevant studies on mannitol treatment of supratentorial HICH were identified from the databases including PubMed, EMBASE, Cochrane Library, VIP, CNKI, and Wan Fang. Our outcome measures included the incidence of hematoma enlargement, the neurologic function improvement rate, mortality, and the incidence of aggravated brain edema. The subgroup analysis was performed to explore the impact of study type, year of publication, intervention time, and dose on the outcome measures. Publication bias was assessed by the funnel plot. RESULTS: Thirty-four studies consisting of 3627 patients with supratentorial HICH were included in this study (from 2000 to 2018). Significant statistical difference was found between the mannitol and nonmannitol group in terms of all the outcome measures, including the incidence of hematoma enlargement (P < 0.00001), the neurologic function improvement rate (P < 0.00001), mortality (P < 0.00001), and the incidence of aggravated cerebral edema (P = 0.0002). In subgroup analysis, the results showed that study type and intervention time did not significantly affect the outcome measures. No significant statistical difference was found in the subgroups of publication time (after 2010) (P = 0.08) and half-dose of mannitol (P = 0.20) on mortality. In addition, the further analysis showed that whatever the dose (250 mL or 125 mL) and intervention time (<24, <12, or <6 hours), mannitol could lead to hematoma enlargement. CONCLUSIONS: For patients without obvious symptoms of intracranial hypertension or cerebral palsy, it is not recommended to use mannitol routinely in the early stage of supratentorial HICH. More high-quality trials should be included to confirm our conclusion and to ascertain the best time and dose of mannitol to use.
引用
- Sun S, Li Y, Zhang H, et al. The Effect of Mannitol in the Early Stage of Supratentorial Hypertensive Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis. World Neurosurg. 2018. PMID: 30576817. doi:10.1016/j.wneu.2018.11.249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。